Please login to the form below

Not currently logged in


This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Roche has also reported Sutent-topping results with it’s combination of PD-L1 inhibitor Tecentriq (atezolizumab) and well-established cancer drug Avastin (bevacizumab).

Latest news

More from news
Approximately 29 fully matching, plus 29 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...